CN102065868A - 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途 - Google Patents

诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途 Download PDF

Info

Publication number
CN102065868A
CN102065868A CN2009801237219A CN200980123721A CN102065868A CN 102065868 A CN102065868 A CN 102065868A CN 2009801237219 A CN2009801237219 A CN 2009801237219A CN 200980123721 A CN200980123721 A CN 200980123721A CN 102065868 A CN102065868 A CN 102065868A
Authority
CN
China
Prior art keywords
cancer
globo
fut2
cells
ssea3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801237219A
Other languages
English (en)
Chinese (zh)
Inventor
爱丽丝·L·于
约翰·于
志辉·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of CN102065868A publication Critical patent/CN102065868A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001173—Globo-H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2009801237219A 2008-06-16 2009-06-16 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途 Pending CN102065868A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6196808P 2008-06-16 2008-06-16
US61/061,968 2008-06-16
PCT/US2009/047537 WO2010005735A2 (en) 2008-06-16 2009-06-16 Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment

Publications (1)

Publication Number Publication Date
CN102065868A true CN102065868A (zh) 2011-05-18

Family

ID=41431519

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801237219A Pending CN102065868A (zh) 2008-06-16 2009-06-16 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途

Country Status (11)

Country Link
US (4) US20090317411A1 (https=)
EP (2) EP2303286A4 (https=)
JP (4) JP2011524375A (https=)
KR (1) KR20110031949A (https=)
CN (1) CN102065868A (https=)
AU (2) AU2009268937A1 (https=)
CA (2) CA2728344A1 (https=)
ES (1) ES2570630T3 (https=)
MX (2) MX2010013932A (https=)
NZ (1) NZ590140A (https=)
WO (2) WO2010005735A2 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105026413A (zh) * 2013-01-04 2015-11-04 台湾浩鼎生技股份有限公司 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
CN106573962A (zh) * 2014-08-22 2017-04-19 中央研究院 新颖的聚糖共轭物及其用途
CN107407673A (zh) * 2015-01-24 2017-11-28 中央研究院 新颖聚醣结合物及其使用方法
CN107430127A (zh) * 2015-01-24 2017-12-01 中央研究院 癌症标记及其使用方法
CN107427564A (zh) * 2014-09-15 2017-12-01 台湾浩鼎生技股份有限公司 免疫原性/治疗性糖缀合物组合物及其用途
CN107407673B (zh) * 2015-01-24 2019-07-16 中央研究院 新颖聚醣结合物及其使用方法
CN110062767A (zh) * 2016-07-29 2019-07-26 台湾浩鼎生技股份有限公司 人抗体、药物组合物和方法
CN110072545A (zh) * 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
CN112513635A (zh) * 2018-05-11 2021-03-16 台湾浩鼎生技股份有限公司 预测人体免疫反应的方法

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
CN102065868A (zh) * 2008-06-16 2011-05-18 中央研究院 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途
ES2477549T3 (es) * 2008-06-16 2014-07-17 Academia Sinica Diagnóstico del cáncer según la concentración de anticuerpos contra Globo H y sus fragmentos
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
CN102858370A (zh) * 2010-05-03 2013-01-02 Dcb-美国有限责任公司 用作疫苗的多糖与去毒大肠杆菌(e.coli)不耐热肠毒素(lt)的偶联
US9493580B2 (en) 2010-06-11 2016-11-15 Sloan-Kettering Institute For Cancer Research Multivalent glycopeptide constructs and uses thereof
DK2608796T3 (en) * 2010-08-05 2019-03-18 Seattle Genetics Inc Inhibition of protein fucosylation in vivo using fucose analogues
GB201013767D0 (en) * 2010-08-17 2010-09-29 Isis Innovation Identification of ligands and their use
US20120288525A1 (en) * 2011-05-11 2012-11-15 Chakravarty Sumana Pharmaceutical compositions comprising attenuated plasmodium sporozoites and glycolipid adjuvants
JP6187939B2 (ja) * 2012-03-08 2017-08-30 学校法人産業医科大学 がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
WO2014031875A1 (en) 2012-08-23 2014-02-27 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
US10307471B2 (en) 2013-05-02 2019-06-04 National Institute Of Advanced Industrial Science And Technology Immunity inducer for saccharide antigens
EP3013365B1 (en) * 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) * 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
GB201313352D0 (en) 2013-07-26 2013-09-11 Isis Innovation Identification of peptide ligands
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
AU2014391422A1 (en) 2013-09-17 2015-12-17 Obi Pharma, Inc. Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) * 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3119424A4 (en) 2014-03-19 2017-09-13 MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
CA2941029C (en) 2014-04-10 2021-02-16 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CA2950423A1 (en) 2014-05-27 2015-12-03 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102512592B1 (ko) 2014-05-27 2023-03-21 아카데미아 시니카 항-ｈｅｒ2 글리코항체 및 이의 용도
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
CN106714829A (zh) 2014-05-28 2017-05-24 中央研究院 抗TNF‑α醣抗体及其用途
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
CA2960712A1 (en) * 2014-09-08 2016-03-17 Academia Sinica Human inkt cell activation using glycolipids
US20170348414A1 (en) * 2014-09-15 2017-12-07 Wayne State University Novel synthetic anticancer, antifungal, and antibacterial vaccines
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
CA2973886A1 (en) 2015-01-30 2016-08-04 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN105067813A (zh) * 2015-07-23 2015-11-18 丁晓昆 一种快速检测t-合酶活性的方法
KR20180050339A (ko) * 2015-09-04 2018-05-14 오비아이 파머 인코퍼레이티드 글리칸 어레이 및 사용 방법
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
CN109379889A (zh) 2016-04-22 2019-02-22 台湾浩鼎生技股份有限公司 通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
WO2018054353A1 (en) * 2016-09-23 2018-03-29 Chang, Chih-Long Anti-globo h antibodies
TWI822055B (zh) * 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
WO2020006176A1 (en) 2018-06-27 2020-01-02 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
JP7319362B2 (ja) * 2018-11-02 2023-08-01 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド マクロフィリン結合医薬アッセイに使用するための結合競合剤およびその使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544952B1 (en) * 1994-03-15 2003-04-08 Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the globo-H epitope and uses thereof
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
EP0996455B1 (en) * 1997-04-16 2009-12-16 Sloan-Kettering Institute For Cancer Research Alpha-o-linked glycoconjugates with clustered (2,6)-st epitopes, methods of preparation and uses thereof
AU2001241783A1 (en) * 2000-02-29 2001-09-12 Sloan-Kettering Institute For Cancer Research Affinity matrix bearing tumor-associated antigens
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
EP1458242A4 (en) 2001-07-06 2006-06-07 Sloan Kettering Inst Cancer COMPREHENSIVE CONJUGATED VACCINE AGAINST CANCER
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
US7132101B2 (en) * 2002-02-27 2006-11-07 Duquesne University Of The Holy Ghost Compositions and methods for eliciting an immune response to gram-negative bacterial infections
WO2004028475A2 (en) * 2002-09-27 2004-04-08 Biomira, Inc. Glycosylceramide analogues
US20060035267A1 (en) * 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
GB0313916D0 (en) * 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
WO2006068758A2 (en) * 2004-11-19 2006-06-29 The Scripps Research Institute Detection, prevention and treatment of breast cancer
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
JP5090928B2 (ja) 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体
KR100764678B1 (ko) * 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
AU2007269299B2 (en) * 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
CN101225383B (zh) * 2007-01-15 2011-10-12 燕秋 用于抑制LeY糖抗原合成的岩藻糖基转移酶Ⅰ和Ⅳ的RNA干涉序列及重组干涉质粒
JP5357782B2 (ja) * 2007-02-21 2013-12-04 バクシネックス インコーポレーティッド 抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
JP2010523724A (ja) * 2007-04-13 2010-07-15 アカデミア シニカ α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用
CA2688268A1 (en) * 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
CN102065868A (zh) * 2008-06-16 2011-05-18 中央研究院 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途
US8383767B2 (en) * 2008-06-27 2013-02-26 Academia Sinica Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain
US7928077B2 (en) * 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499679B (zh) * 2013-01-04 2021-07-06 台湾浩鼎生技股份有限公司 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
CN105026413A (zh) * 2013-01-04 2015-11-04 台湾浩鼎生技股份有限公司 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
CN111499679A (zh) * 2013-01-04 2020-08-07 台湾浩鼎生技股份有限公司 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
CN106573962B (zh) * 2014-08-22 2020-06-05 中央研究院 新颖的聚糖共轭物及其用途
CN106573962A (zh) * 2014-08-22 2017-04-19 中央研究院 新颖的聚糖共轭物及其用途
CN107427564A (zh) * 2014-09-15 2017-12-01 台湾浩鼎生技股份有限公司 免疫原性/治疗性糖缀合物组合物及其用途
TWI726850B (zh) * 2014-09-15 2021-05-11 台灣浩鼎生技股份有限公司 免疫/治療性醣共軛物組合物及其用途
CN107430127A (zh) * 2015-01-24 2017-12-01 中央研究院 癌症标记及其使用方法
CN107407673B (zh) * 2015-01-24 2019-07-16 中央研究院 新颖聚醣结合物及其使用方法
CN107407673A (zh) * 2015-01-24 2017-11-28 中央研究院 新颖聚醣结合物及其使用方法
CN110072545A (zh) * 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
CN110062767A (zh) * 2016-07-29 2019-07-26 台湾浩鼎生技股份有限公司 人抗体、药物组合物和方法
CN110062767B (zh) * 2016-07-29 2023-07-11 台湾浩鼎生技股份有限公司 人抗体、药物组合物和方法
CN112513635A (zh) * 2018-05-11 2021-03-16 台湾浩鼎生技股份有限公司 预测人体免疫反应的方法
CN112513635B (zh) * 2018-05-11 2024-04-16 台湾浩鼎生技股份有限公司 预测人体免疫反应的方法

Also Published As

Publication number Publication date
US8268969B2 (en) 2012-09-18
AU2009269127A1 (en) 2010-01-14
JP2011524375A (ja) 2011-09-01
ES2570630T3 (es) 2016-05-19
JP5628158B2 (ja) 2014-11-19
WO2010005735A3 (en) 2010-03-18
US20120328646A1 (en) 2012-12-27
EP2310047A1 (en) 2011-04-20
EP2310047B1 (en) 2016-03-30
KR20110031949A (ko) 2011-03-29
CA2728341C (en) 2019-07-02
US20100136042A1 (en) 2010-06-03
MX350230B (es) 2017-08-30
JP2014144958A (ja) 2014-08-14
US20150273034A1 (en) 2015-10-01
US9028836B2 (en) 2015-05-12
CA2728344A1 (en) 2010-01-14
US20090317411A1 (en) 2009-12-24
JP2016020363A (ja) 2016-02-04
CA2728341A1 (en) 2010-01-14
JP2011524417A (ja) 2011-09-01
JP6151319B2 (ja) 2017-06-21
AU2009269127B2 (en) 2013-12-05
MX2010013932A (es) 2013-03-01
AU2009268937A1 (en) 2010-01-14
EP2303286A2 (en) 2011-04-06
US9603913B2 (en) 2017-03-28
EP2303286A4 (en) 2011-12-28
JP5795655B2 (ja) 2015-10-14
WO2010005598A1 (en) 2010-01-14
NZ590140A (en) 2012-07-27
WO2010005735A2 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
CN102065868A (zh) 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途
CN102215862B (zh) Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
JP7330174B2 (ja) オートファジーをモジュレーションするための方法及び医薬組成物
CN106794194A (zh) 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂
Kwon et al. Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers
TWI583393B (zh) 免疫原性組合物、包含其之疫苗與治療劑及其用途
US20160130330A1 (en) Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
Li et al. Caveolin-1–mediated negative signaling plays a critical role in the induction of regulatory dendritic cells by DNA and protein coimmunization
US20070281041A1 (en) Compositions and Methods Involving MDA-7 for the Treatment of Cancer
JP2024504924A (ja) 腫瘍及びがんを予防するための組成物及び方法
US9795660B2 (en) Id-protein targeted tumor cell vaccine
AU2014201215B2 (en) Globo h and related anti-cancer vaccines with novel glycolipid adjuvants
US9566304B2 (en) Pharmaceutical composition for preventing or treating cancers comprising dendritic cells with Dab2 gene silenced
EP4691490A1 (en) Pharmaceutical composition for treating and/or preventing cancer
CA3286171A1 (en) Pharmaceutical composition for treating and/or preventing cancer
HK1153645B (en) Globo h and related anti-cancer vaccines with novel glycolipid adjuvants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110518